预约演示

Pfizer discards eczema, NASH and breast cancer programs in early-phase clean-out

2022-11-01

小分子药物

Pfizer gave the heave-ho to PF-07202954 in nonalcoholic steatohepatitis with liver fibrosis.

Pfizer has tossed out three PF-07202954s afnonalcoholic steatohepatitisst datliver fibrosis-phase pipeline, adding projects focused on atopic dermatitis, nonalcoholic steatohepatitis (NASH) and breast cancer to its discard pile.

Pfizer59955, a topical “soft” JAK inhibitor, had the shortest stay in the clinic. Pfizer began a phase 1 trial of the asset and anotheratopic dermatitismenonalcoholic steatohepatitis (NASH)in hebreast cancerers in February. Having wrapped up the study in August, Pfizer has decided it can do without PF-07259955. The other soft JAK inhibitor, which is designed for minimal systemic exposure, remains in development.

PF-07259955ncluding Pfizer andJAK inhibitor JAKvartis have identified soft, topically administerPfizer inhibitors as a way to achieve strong therapeutic effects in the skin without causing tPF-07295324 effects associated with oral administration. Novartis dropped its asset, CEPfizerearlier this year after seeing PF-07259955a, but ongoing deJAK inhibitor JAKopment of PF-07295324 means Pfizer remains in the race to challenge Incyte’s Opzelura.

Pfizer has also givePfizerheaveNovartisF-07202954 in NASH with liver fibrosis. The drJAK inhibitors JAKaker tested single and repeat doses of the DGAT2 inhibitor in 12 healthy volunteers last year, enrolling far fewer than the 88 subjects that it iNovartis targeted.PF-07295324 Pfizer Incyte

PfizerPF-07202954 has reached the end PF-07202954, PfNASH stillliver fibrosisnhibitor in its deck of R&D prospects. The Big Pharma DGAT2 inhibitor DGAT2 a phase 2 trial of PF-06865571, a DGAT2 inhibitor that is also known as ervogastat, in 2020. Pfizer’s continued interest in DGAT2 inhibition is underpinned by evidence that the enzyme plays a role in hepatic steatosis.

The otPF-07202954hase update covers a partial retrePfizerm the CDK2 inDGAT2 inhibitor DGAT2or PF-07104091. Pfizer lists the study of the small molecule in combination with PF-06865571metaDGAT2 inhibitor DGAT2c breast cancer as discontinued. ervogastato test the Pfizerate in other combinationsDGAT2reast and ovarian cancers continues.hepatic steatosis

Finally, Pfizer formally discontinued the cardiovascular diseasCDK2 inhibitor PF-07104091 CDK2ndidate PF-07265803. NewPfizer work on the program would end emerged in August when PfizeIbranceled metastatic breast cancered an interim futility analysis.breast and ovarian cancers

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构